CA2575932A1 - Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases - Google Patents

Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases Download PDF

Info

Publication number
CA2575932A1
CA2575932A1 CA002575932A CA2575932A CA2575932A1 CA 2575932 A1 CA2575932 A1 CA 2575932A1 CA 002575932 A CA002575932 A CA 002575932A CA 2575932 A CA2575932 A CA 2575932A CA 2575932 A1 CA2575932 A1 CA 2575932A1
Authority
CA
Canada
Prior art keywords
medicament according
dispersion
propellant
pharmaceutically acceptable
finely divided
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002575932A
Other languages
English (en)
French (fr)
Inventor
Theodore L. Lithgow
Paul T. Medeiros
Keith Anthony Ellway
Thomas J. Higgins
Richard R. Lorber
Bruce A. Malcolm
Elaine Radwanski
Heribert W. Staudinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2575932A1 publication Critical patent/CA2575932A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002575932A 2004-08-04 2005-08-03 Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases Abandoned CA2575932A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59861804P 2004-08-04 2004-08-04
US60/598,618 2004-08-04
PCT/US2005/027428 WO2006017505A2 (en) 2004-08-04 2005-08-03 Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases

Publications (1)

Publication Number Publication Date
CA2575932A1 true CA2575932A1 (en) 2006-02-16

Family

ID=35583475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002575932A Abandoned CA2575932A1 (en) 2004-08-04 2005-08-03 Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases

Country Status (6)

Country Link
US (1) US20060030550A1 (enExample)
EP (1) EP1819329A2 (enExample)
JP (2) JP2008509143A (enExample)
CA (1) CA2575932A1 (enExample)
MX (1) MX2007001561A (enExample)
WO (1) WO2006017505A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902177B2 (en) 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
EP1981475A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
CA2641616A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
JP2009526064A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 薬学的調合物
CN1907293B (zh) * 2006-08-22 2012-07-04 蔡海德 一种治疗肺炎的组合药物及其制备方法
US20080069874A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis
WO2009079078A1 (en) 2007-12-14 2009-06-25 Labogroup S.A.S. Delivering aerosolizable food products
TW201016215A (en) * 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
EP4241771A3 (en) 2013-11-08 2023-11-22 Antivirus Therapeutics Methods and compositions for treating sepsis
CN106470724A (zh) * 2014-06-25 2017-03-01 奥普蒂诺斯公司 鼻腔给药
US10139321B2 (en) * 2016-07-29 2018-11-27 Alpha-Tec Systems, Inc. Mucolytic tablet for a sample collection device
CN107669635A (zh) * 2016-09-30 2018-02-09 青岛大学 一种用于治疗呼吸系统疾病的气雾剂及其制备方法
CN107513071B (zh) * 2017-08-30 2019-06-04 新乡医学院 一种多功能鬼臼毒素衍生物及其制备方法和应用
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN111166719A (zh) * 2019-12-31 2020-05-19 郑州都灵兽药科技有限公司 一种泰拉霉素肠溶颗粒的制备方法
GB202103803D0 (en) * 2021-03-18 2021-05-05 Queens Univ Of Belfast Anti-viral therapy
CN114177176B (zh) * 2021-12-04 2022-07-12 中国农业科学院兰州兽医研究所 化合物盐酸赛庚啶在制备预防或治疗非洲猪瘟药物中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1618005A1 (de) * 1966-09-22 1971-09-09 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
DE3106995A1 (de) * 1981-02-25 1982-08-19 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von guajocalglycerinether
WO1985003707A1 (en) * 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US4731447A (en) * 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
SK140493A3 (en) * 1991-06-10 1994-10-05 Schering Corp Non-chlorofluorocarbon aerosol formulations
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5349068A (en) * 1992-04-15 1994-09-20 Sterling Winthrop Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5894179A (en) * 1997-12-17 1999-04-13 Emerson Electric Co. Motor with strategically placed connector block
WO2001019322A2 (en) * 1999-09-17 2001-03-22 Smithkline Beecham Corporation Use of csaids in rhinovirus infection
NZ519797A (en) * 2000-02-03 2005-05-27 Schering Corp Treating allergic and inflammatory conditions
NZ523659A (en) * 2000-07-18 2006-01-27 Smithkline Beecham Corp Use of IL-8 receptor antagonists in the treatment of virus infections
DE60119534T2 (de) * 2000-07-28 2007-05-10 Immupharm Aps Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
US7429606B2 (en) * 2001-08-29 2008-09-30 Viropharma Incorporated Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents
GB0123951D0 (en) * 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
EP1471872A2 (en) * 2002-02-04 2004-11-03 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
CA2475971A1 (en) * 2002-02-14 2003-08-21 Viropharma Incorporated Methods of reducing rhinovirus contagion and related compositions
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング　コーポレイション 薬学的組成物
JP2006508178A (ja) * 2002-09-10 2006-03-09 マイクロバイオティクス，インコーポレーテッド 抗菌性ピラゾールカルボン酸ヒドラジド

Also Published As

Publication number Publication date
JP2008509143A (ja) 2008-03-27
MX2007001561A (es) 2007-04-16
WO2006017505A2 (en) 2006-02-16
EP1819329A2 (en) 2007-08-22
JP2008297311A (ja) 2008-12-11
US20060030550A1 (en) 2006-02-09
WO2006017505A3 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
US20060030550A1 (en) Pharmaceutical formulations
US20090221541A1 (en) Pharmaceutical formulations
US20070202050A1 (en) Pharmaceutical Formulations
EP2486942B1 (en) Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) Compositions comprising azelastine and methods of use thereof
JP2008509143A5 (enExample)
US20100144610A1 (en) Pharmaceutical formulations
CN104994854A (zh) 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
JP2011528355A (ja) 充血除去剤およびコルチコステロイドを含む鼻腔内粗製物
US20060110449A1 (en) Pharmaceutical composition
HK1159518A (en) Compositions comprising azelastine and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130508